OmniAb

OABI

Market cap $237M

OmniAb, Inc. (OABI) Q4 2025 Earnings Call Transcript

OmniAb, Inc. (OABI) came out with a quarterly loss of $0.11 per share versus the Zacks Consensus Estimate of a loss of $0.08. This compares to a loss of $0.12 per share a year ago.

EMERYVILLE, Calif.--(BUSINESS WIRE)---- $OABI #OABI--OmniAb, Inc. (NASDAQ: OABI) today reported financial results for the quarter and year ended December 31, 2025, and provided operating and partner program updates. “OmniAb exited 2025 with an expanded base of 107 active partners and a growing portfolio of 407 active programs. Our differentiated technologies support our business outlook and allow us to add programs while maintaining a disciplined cost structure. As our partner pipeline continues to advance, se.

EMERYVILLE, Calif.--(BUSINESS WIRE)---- $OABI #OABI--OmniAb, Inc. (NASDAQ: OABI) today announced that management will participate at the Leerink Global Healthcare Conference taking place March 8-11, 2026, at the W South Beach in Miami. Management will present a corporate overview on Tuesday, March 10th at 3:40 p.m. Eastern time and will hold one-on-one meetings with investors registered for the event. Investors interested in scheduling a meeting with OmniAb management should contact their Leerink Partners repr.

EMERYVILLE, Calif.--(BUSINESS WIRE)---- $OABI #OABI--OmniAb, Inc. (NASDAQ: OABI) will report financial results for the quarter and year ended December 31, 2025, after the close of the U.S. financial markets on Wednesday, March 4, 2026, and will hold a conference call that same day beginning at 4:30 p.m. Eastern time. Conference Call and Webcast Information What:   OmniAb conference call to discuss fourth quarter 2025 financial results and business updates       Date:   Wednesday, March 4, 2026       Time:   4:.

OmniAb, Inc. (OABI) Discusses Launch and Scientific Overview of OmniUltra Technology Platform Transcript

EMERYVILLE, Calif.--(BUSINESS WIRE)---- $OABI #OABI--OmniAb, Inc. (NASDAQ: OABI) announces the launch of its new OmniUltra™ platform, the industry's first and only transgenic chicken engineered to express ultralong CDRH3 domains on a human antibody framework, at the 2025 Antibody Engineering & Therapeutics (AET) Conference underway in San Diego. OmniUltra is a versatile in vivo discovery platform that extends beyond traditional antibody modalities into the peptide space, enabling multiple therapeutic appli.

EMERYVILLE, Calif.--(BUSINESS WIRE)---- $OABI #OABI--OmniAb, Inc. (NASDAQ: OABI) today announced it will hold a virtual investor event to showcase the launch of OmniUltra™ on Monday, December 15, 2025, beginning at 5:00 p.m. Eastern time. The event is expected to last approximately one hour and will include a review of OmniAb's newest technology offering, OmniUltra, the industry's only transgenic chicken engineered to express ultralong CDRH3 domains on a human antibody framework. Management will provide an ove.

EMERYVILLE, Calif. & DENVER--(BUSINESS WIRE)---- $OABI #OABI--OmniAb, Inc. (NASDAQ: OABI) and ArrowMark Partners (“ArrowMark”) today announced the signing of a license and services agreement for novel OmniAb-derived antibody discovery programs with Mabtrx Biosciences, a wholly owned subsidiary of AMVKG LS, a joint venture (JV) between ArrowMark and Viking Global Investors (“Viking”). Under the terms of the license and services agreement, OmniAb will receive revenue for services performed as well as potential e.

OmniAb, Inc. ( OABI ) Q3 2025 Earnings Call November 4, 2025 4:30 PM EST Company Participants Kurt Gustafson - Executive VP of Finance & CFO Matthew Foehr - President, CEO & Director Conference Call Participants Michael Almisry - Leerink Partners LLC, Research Division Alexander Xenakis Matthew Hewitt - Craig-Hallum Capital Group LLC, Research Division Brendan Smith - TD Cowen, Research Division Presentation Operator " Kurt Gustafson Executive VP of Finance & CFO " Matthew Foehr President, CEO & Director " Michael Almisry Leerink Partners LLC, Research Division " Leerink Partners LLC, Research Division Unknown Analyst " Alexander Xenakis " Truist Securities | Matthew Hewitt Craig-Hallum Capital Group LLC, Research Division " Craig-Hallum Capital Group LLC, Research Division Brendan Smith TD Cowen, Research Division " TD Cowen, Research Division Unknown Analyst " Operator Good afternoon, and welcome to OmniAb's Third Quarter 2025 Financial Results and Business Update Conference Call. [Operator Instructions] As a reminder, this conference is being recorded.